Baseline diastolic dysfunction as a predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancer

Breast Cancer Research and Treatment

Volumn 130, Issue 3, 2011, Pages 845-854

  Cochet, Alexandre ^a,b   Quilichini, Gaetan ^a   Dygai Cochet, Inna ^a   Touzery, Claude ^a   Toubeau, Michel ^a   Berriolo Riedinger, Alina ^a   Coudert, Bruno ^a   Cottin, Yves ^c   Fumoleau, Pierre ^a   Brunotte, François ^a,b  

^a CENTRE GEORGES FRANÇOIS LECLERC   (France)

^b CNRS   (France)

^c HÔPITAL DU BOCAGE   (France)

Author keywords

Breast cancer; Diastolic function; Radionuclide angiocardiography; Trastuzumab mediated cardiotoxicity

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; TRASTUZUMAB;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER STAGING; CARDIOTOXICITY; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG SAFETY; EARLY CANCER; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FILLING; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; SCINTIANGIOGRAPHY; TREATMENT DURATION;

AGED; ANTHRACYCLINES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; EPIRUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RISK FACTORS; VENTRICULAR DYSFUNCTION;

EID: 82255174926     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1714-9     Document Type: Article

References (53)

1. P Carter L Presta CM Gorman, et al. 1992 Humanization of an anti-p185HER2 antibody for human cancer therapy Proc Natl Acad Sci USA 89 4285 4289 1350088 10.1073/pnas.89.10.4285 1:CAS:528:DyaK3sXitFSqtb0%3D
2. EH Romond EA Perez J Bryant, et al. 2005 Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 1673 1684 16236738 10.1056/NEJMoa052122 1:CAS:528:DC%2BD2MXhtFansr3F (Pubitemid 41464706)
3. A Seidman C Hudis MK Pierri, et al. 2002 Cardiac dysfunction in the trastuzumab clinical trials experience J Clin Oncol 20 1215 1221 11870163 10.1200/JCO.20.5.1215 1:CAS:528:DC%2BD38XisVWmuro%3D (Pubitemid 34177427)
4. MS Ewer SM Lippman 2005 Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity J Clin Oncol 23 2900 2902 15860848 10.1200/JCO.2005.05.827 1:CAS:528:DC%2BD2MXkslGhurg%3D (Pubitemid 46224107)
5. MS Ewer MT Vooletich JB Durand, et al. 2005 Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment J Clin Oncol 23 7820 7826 16258084 10.1200/JCO.2005.13.300 1:CAS:528:DC%2BD2MXht1Cqs7bP (Pubitemid 46657379)
6. V Guarneri DJ Lenihan V Valero, et al. 2006 Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience J Clin Oncol 24 4107 4115 16908934 10.1200/JCO.2005.04. 9551 1:CAS:528:DC%2BD28XhtVantb3F (Pubitemid 46622286)
7. D Wadhwa N Fallah-Rad D Grenier, et al. 2009 Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study Breast Cancer Res Treat 117 357 364 19082707 10.1007/s10549-008-0260-6 1:CAS:528:DC%2BD1MXpvF2gsLg%3D
8. DB Sawyer C Zuppinger TA Miller HM Eppenberger TM Suter 2002 Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity Circulation 105 1551 1554 11927521 10.1161/01.CIR.0000013839. 41224.1C 1:CAS:528:DC%2BD38XjtlCmtLc%3D (Pubitemid 34297631)
9. PJ Perik EG de Vries JA Gietema, et al. 2007 Serum HER2 levels are increased in patients with chronic heart failure Eur J Heart Fail 9 173 177 16860598 10.1016/j.ejheart.2006.05.010 1:CAS:528:DC%2BD2sXhvVyrtL8%3D (Pubitemid 46394075)
10. A Jannazzo J Hoffman M Lutz 2008 Monitoring of anthracycline-induced cardiotoxicity Ann Pharmacother 42 99 104 18094345 1:CAS:528: DC%2BD1cXhvVClt78%3D
11. BH Lee LS Goodenday GJ Muswick WA Yasnoff RF Leighton RT Skeel 1987 Alterations in left ventricular diastolic function with doxorubicin therapy J Am Coll Cardiol 9 184 188 3794095 10.1016/S0735-1097(87)80099-2 1:STN:280:DyaL2s%2FosVektA%3D%3D (Pubitemid 17219564)
12. B Marchandise E Schroeder A Bosly, et al. 1989 Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics Am Heart J 118 92 98 2741800 10.1016/0002-8703(89)90077-X 1:STN:280:DyaL1MzgtVGmsA%3D%3D (Pubitemid 19183582)
13. Y Cottin C Touzery B Coudert, et al. 1995 Impairment of diastolic function during short-term anthracycline chemotherapy Br Heart J 73 61 64 7888264 10.1136/hrt.73.1.61 1:STN:280:DyaK2M7psVOksA%3D%3D
14. RO Bonow DR Rosing SL Bacharach, et al. 1981 Effects of verapamil on left ventricular systolic function and diastolic filling in patients with hypertrophic cardiomyopathy Circulation 64 787 796 7196813 10.1161/01.CIR.64.4. 787 1:STN:280:DyaL38%2Fgt1KmsA%3D%3D (Pubitemid 11030133)
15. FM Fouad JM Slominski RC Tarazi 1984 Left ventricular diastolic function in hypertension: relation to left ventricular mass and systolic function J Am Coll Cardiol 3 1500 1506 6232306 10.1016/S0735-1097(84)80289-2 1:STN:280:DyaL2c7os1GgtQ%3D%3D (Pubitemid 14110106)
16. RO Bonow 1991 Radionuclide angiographic evaluation of left ventricular diastolic function Circulation 84 I208 I215 1884488 1:STN:280: DyaK3Mzls1Kruw%3D%3D
17. MM Redfield SJ Jacobsen JC Burnett Jr DW Mahoney KR Bailey RJ Rodeheffer 2003 Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic J Am Med Assoc 289 194 202 10.1001/jama.289.2.194 (Pubitemid 36068707)
18. National Cancer Research Institute. UK clinical guidelines for the use of adjuvant trastuzumab (Herceptin) with or following chemotherapy in HER2-positive early breast cancer. Available at http://www.dh.gov.uk/assetRoot/ 04/12/63/84/04126384.pdf
19. KJ Lee AE Southee GJ Bautovich, et al. 1989 Normalised radionuclide measures of left ventricular diastolic function Eur J Nucl Med 15 123 127 2540982 10.1007/BF00254623 1:STN:280:DyaL1M3jtFyhtA%3D%3D (Pubitemid 19080484)
20. RH Jones P McEwan GE Newman, et al. 1981 Accuracy of diagnosis of coronary artery disease by radionuclide management of left ventricular function during rest and exercise Circulation 64 586 601 6266694 10.1161/01.CIR.64.3.586 1:STN:280:DyaL3M3lvFSmsQ%3D%3D (Pubitemid 11061629)
21. RO Bonow AL Picone CL McIntosh, et al. 1985 Survival and functional results after valve replacement for aortic regurgitation from 1976 to 1983: impact of preoperative left ventricular function Circulation 72 1244 1256 4064269 10.1161/01.CIR.72.6.1244 1:STN:280:DyaL28%2Fltlyquw%3D%3D (Pubitemid 16126805)
22. A Gradman P Deedwania R Cody, et al. 1989 Predictors of total mortality and sudden death in mild to moderate heart failure. captopril-digoxin study group J Am Coll Cardiol 14 564 570 2768707 10.1016/0735-1097(89)90093-4 1:STN:280:DyaL1MzmtVaksw%3D%3D discussion 571-562 (Pubitemid 19229327)
23. M Martin FJ Esteva E Alba, et al. 2009 Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations Oncologist 14 1 11 19147689 10.1634/theoncologist.2008-0137 1:CAS:528:DC%2BD1MXjt1Clt78%3D
24. MJ Piccart-Gebhart M Procter B Leyland-Jones, et al. 2005 Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 1659 1672 16236737 10.1056/NEJMoa052306 1:CAS:528:DC%2BD2MXhtFansr3L (Pubitemid 41464705)
25. AL Jones M Barlow PJ Barrett-Lee, et al. 2009 Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom national cancer research institute recommendations for monitoring Br J Cancer 100 684 692 19259090 10.1038/sj.bjc.6604909 1:CAS:528: DC%2BD1MXisFentb8%3D
26. JL Hare JK Brown R Leano C Jenkins N Woodward TH Marwick 2009 Use of myocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with trastuzumab Am Heart J 158 294 301 19619708 10.1016/j.ahj.2009.05.031 1:CAS:528:DC%2BD1MXos12qs7o%3D
27. N Fallah-Rad JR Walker A Wassef, et al. 2011 The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy J Am Coll Cardiol 57 2263 2270 21616287 10.1016/j.jacc.2010.11.063 1:CAS:528:DC%2BC3MXot1yjsbg%3D
28. RO Bonow SL Bacharach MV Green, et al. 1981 Impaired left ventricular diastolic filling in patients with coronary artery disease: assessment with radionuclide angiography Circulation 64 315 323 7249299 10.1161/01.CIR.64.2.315 1:STN:280:DyaL3M3jsV2gtQ%3D%3D (Pubitemid 11093422)
29. DA Martinez DJ Guhl WC Stanley AC Vailas 2003 Extracellular matrix maturation in the left ventricle of normal and diabetic swine Diabetes Res Clin Pract 59 1 9 12482636 10.1016/S0168-8227(02)00178-X 1:CAS:528: DC%2BD38XptlWnuro%3D (Pubitemid 35461904)
30. J Lumens T Delhaas T Arts BR Cowan AA Young 2006 Impaired subendocardial contractile myofiber function in asymptomatic aged humans, as detected using MRI Am J Physiol Heart Circ Physiol 291 H1573 H1579 16679404 10.1152/ajpheart. 00074.2006 1:CAS:528:DC%2BD28XhtFegtrbN (Pubitemid 44497660)
31. J Wang DS Khoury Y Yue G Torre-Amione SF Nagueh 2008 Preserved left ventricular twist and circumferential deformation, but depressed longitudinal and radial deformation in patients with diastolic heart failure Eur Heart J 29 1283 1289 18385117 10.1093/eurheartj/ehn141 1:CAS:528:DC%2BD1cXhtlKit7zM (Pubitemid 351768130)
32. B Hesse TB Lindhardt W Acampa, et al. 2008 EANM/ESC guidelines for radionuclide imaging of cardiac function Eur J Nucl Med Mol Imaging 35 851 885 18224320 10.1007/s00259-007-0694-9 1:STN:280:DC%2BD1c7ovFentw%3D%3D
33. JA Arrighi R Soufer 1995 Left ventricular diastolic function: physiology, methods of assessment, and clinical significance J Nucl Cardiol 2 525 543 9420835 10.1016/S1071-3581(05)80045-5 1:STN:280:DyaK1c%2Fot1Cjtw%3D%3D (Pubitemid 26013014)
34. RO Bonow DF Vitale SL Bacharach BJ Maron MV Green 1988 Effects of aging on asynchronous left ventricular regional function and global ventricular filling in normal human subjects J Am Coll Cardiol 11 50 58 3335706 10.1016/0735-1097(88)90166-0 1:STN:280:DyaL1c%2FovVeluw%3D%3D (Pubitemid 18029035)
35. ZX He J Darcourt JP Camous, et al. 1992 Correlations of left ventricular diastolic parameters and heart rate: assessment through right ventricular pacing Eur J Nucl Med 19 343 348 1612096 10.1007/BF00177056 1:STN:280: DyaK38zgs12rsg%3D%3D
36. HJ Muntinga F van den Berg HR Knol, et al. 1997 Normal values and reproducibility of left ventricular filling parameters by radionuclide angiography Int J Card Imaging 13 165 171 9110196 10.1023/A:1005704415207 1:STN:280:DyaK2s3msVelsQ%3D%3D discussion 173 (Pubitemid 27130279)
37. A Negro BK Brar KF Lee 2004 Essential roles of Her2/erbB2 in cardiac development and function Recent Prog Horm Res 59 1 12 14749494 10.1210/rp.59.1.1 1:CAS:528:DC%2BD2cXisFKhtrc%3D (Pubitemid 41327144)
38. DJ Slamon B Leyland-Jones S Shak, et al. 2001 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 783 792 11248153 10.1056/NEJM200103153441101 1:CAS:528:DC%2BD3MXisVGktrc%3D (Pubitemid 32222155)
39. E Tan-Chiu G Yothers E Romond, et al. 2005 Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B:31 J Clin Oncol 23 7811 7819 16258083 10.1200/JCO.2005.02.4091 1:CAS:528:DC%2BD2MXht1Cqs7bN (Pubitemid 46657378)
40. M Guglin G Hartlage C Reynolds R Chen V Patel 2009 Trastuzumab-induced cardiomyopathy: not as benign as it looks? A retrospective study J Cardiac Fail 15 651 657 10.1016/j.cardfail.2009.04.011 1:CAS:528:DC%2BD1MXhtFyntL7L
41. L Gianni 2009 Never use anthracyclines with trastuzumab: it is time to reconsider the taboo Breast Cancer Res Treat 117 599 601 19387827 10.1007/s10549-009-0402-5
42. L Gianni W Eiermann V Semiglazov, et al. 2010 Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort Lancet 375 377 384 20113825 10.1016/S0140-6736(09) 61964-4 1:CAS:528:DC%2BC3cXht12ltLk%3D
43. F Petrelli K Borgonovo M Cabiddu M Ghilardi S Barni 2011 Neoadjuvant chemotherapy and concomitant trastuzumab in breast cancer: a pooled analysis of two randomized trials Anticancer Drugs 22 128 135 21218604 10.1097/CAD. 0b013e32834120aa 1:CAS:528:DC%2BC3cXhsF2gs7nF
44. RB Costa G Kurra L Greenberg CE Geyer 2010 Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer Ann Oncol 21 2153 2160 20351072 10.1093/annonc/mdq096 1:STN:280:DC%2BC3cbhtl2htw%3D%3D
45. SD Russel KL Blackwell J Lawrence, et al. 2010 Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the national surgery adjuvant breast and bowel project B-31 and the north central cancer treatment group N9831 clinical trials J Clin Oncol 28 3416 3421 10.1200/JCO.2009.23.6950
46. M Procter TM Suter E de Azambuja, et al. 2010 Long-term assessment of trastuzumab-related cardiac adverse events in the herceptin adjuvant (HERA) trial J Clin Oncol 28 3422 3428 20530280 10.1200/JCO.2009.26.0463
47. T Chen T Xu Y Li, et al. 2010 Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis Cancer Treat Rev 37 312 320 20952131 10.1016/j.ctrv.2010.09.001
48. LA Smith VR Cornelius CJ Plummer, et al. 2010 Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review, meta-analysis of randomised controlled trials BMC Cancer 10 337 20587042 10.1186/1471-2407-10-337
49. M Untch M Muscholl S Tjulandin, et al. 2010 First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the herceptin, cyclophosphamide, and epirubicin (HERCULES) trial J Clin Oncol 28 1473 1480 20177030 10.1200/JCO.2009.21.9709 1:CAS:528: DC%2BC3cXltFGhsLo%3D
50. SJ Lester AJ Tajik RA Nishimura JK Oh BK Khandheria JB Seward 2008 Unlocking the mysteries of diastolic function: deciphering the Rosetta Stone 10 years later J Am Coll Cardiol 51 679 689 18279730 10.1016/j.jacc.2007.09.061 (Pubitemid 351221211)
51. AN DeMaria TW Wisenbaugh MD Smith MR Harrison MR Berk 1991 Doppler echocardiographic evaluation of diastolic dysfunction Circulation 84 I288 I295 1884498 1:STN:280:DyaK3Mzls1Kquw%3D%3D
52. N Fallah-Rad M Lytwyn T Fang I Kirkpatrick DS Jassal 2008 Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy J Cardiovasc Magn Reson 10 5 18272009 10.1186/1532-429X-10-5
53. DP Leong CG De Pasquale JB Selvanayagam 2010 Heart failure with normal ejection fraction: the complementary roles of echocardiography and CMR imaging JACC Cardiovasc Imaging 3 409 420 20394903 10.1016/j.jcmg.2009.12.011